



**BCIL Biotech Consortium India Limited**

# THERAPEUTIC COMPOSITION FOR QUICK HEALING OF WOUNDS AND ASSOCIATED INFLAMMATION

**TECHNOLOGY AVAILABLE FOR TRANSFER**

## UNMET NEED / OPPORTUNITIES

- Biologics and immune selective anti-inflammatory derivatives are the promising drugs classes that will play the main role in the market.
- Global Market for **Anti-inflammatory Therapeutics is USD 97.8 Billion** for 2020 Market forecast to grow at **CAGR of 4.8%**
- Global Market for **Wound Care Market USD 19.8 Billion** for 2021 Market forecast to grow at **CAGR of 7.6%**
- Commercially available Biologic Anti-inflammatory drugs are used essentially for Arthritis patients and can be categorized in in three such as a. TNF inhibitor, b. B-cell inhibitors, and c. Interleukin-1 blockers.
- The present technology as a product, focuses on a broad- spectrum inflammatory disease and targets inhibition of Mast cells as they are first line of inflammatory response

## TECHNOLOGY

- The **recombinant rPPE2 protein sequence therapeutic composition** for **Scar free** wound healing and associated inflammation
- Invention provides a **Formulation** (Gel/Injection forms) and its **method of preparation**
- The technology inhibits **stem cell factor (SCF)** which is responsible for **mast cell** development and activation
- The rPPE2 is **short sequence** for easy cellular delivery
- rPPE2 protein comprising **SEQ ID NO: 1** (sequence of 556 amino acids) is **NOVEL** and associated with scar free wound healing

## INTELLECTUAL PROPERTY


- Patent Published in India and USA

## UNIQUE SELLING PROPOSITION

- Novel protein-based **wound and associated inflammation healing** formulation
- **Scar free** wound healing (Gel: cosmetic Industry)
- **Short protein sequence** for an easy delivery
- Effective against **Excisional wound and local inflammation** tissue injury
- Drug is **Long acting (16- 21 days)**
- Dosage reduced to almost **one third of the standard drugs**
- **Single injectable dose** can be developed in other forms such as capsules, pills, tablet, spray or ointment

## STAGE OF DEVELOPMENT

- **TRL-4 Proof of concept** established and validated at laboratory scale using *In-Vitro and In-Vivo* Animal models
- **Gel composition/Injection** (efficacy, purity, safety validated)
- Comparative experiment using Diclofenac sodium for injection formulation and EGF (REGEN-D,) for Dermal Gel formulation indicated improved efficacy



## LICENSING OPPORTUNITY

TTO@BCIL is looking for a suitable industrial partner for the Technology development and commercialization

**CONTACT:**

**Dr. Purnima Sharma, Managing Director**  
**BIOTECH CONSORTIUM INDIA LIMITED**  
 V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg,  
 New Delhi:110002 Phone: +91-11-2321 9064-67  
 Fax: +91-11-23219063  
 Email: [tto.bcil@biotech.co.in](mailto:tto.bcil@biotech.co.in) & [info.bcil@biotech.co.in](mailto:info.bcil@biotech.co.in)  
 Website: [www.biotech.co.in](http://www.biotech.co.in)